EconomyNovo stock falls as much as 7% despite $23 billion obesity drug sales target
Novo’s stock fell as much as 7% despite the company setting a $23 billion sales target for its blockbuster obesity drugs.
C
CNBC★★☆☆☆2026-09-21 08:31Original
Novo stock falls as much as 7% despite $23 billion obesity drug sales target
Economy